Australia's Vaxine expects to start Phase II trials for Covid-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Australia's Vaxine expects to start Phase II trials for Covid-19
Vaxine Pty Ltd expects to start Phase II trials of its potential Covid-19 vaccine in the next few weeks after “positive” results from the first stage human study

Australian biotechnology company Vaxine Pty Ltd expects to start Phase II trials of its potential COVID-19 vaccine in the next few weeks after "positive" results from the first stage human study, chairman Nikolai Petrovsky said on Wednesday.

Final stage trials could start within the next three months, he told the Reuters Global Markets Forum chat room in an exclusive interview."It's extremely safe and well-tolerated. We already have that data from the clinical trial. We've not had any bad reactions to the vaccine. That's very positive," he said.

The company is working with South Korea's MedyTox, according to the World Health Organization's list of candidate vaccines. Human trials on 40 people started this month.

No vaccine has yet been approved for COVID-19, the disease caused by the new coronavirus that has killed more than 659,000 people and unleashed economic havoc worldwide.

Vaxine's shot is one of more than two dozen at the human clinical trial stage as the race to tame the pandemic heats up.

Petrovsky said two years is a realistic but ambitious time frame to get a COVID-19 vaccine to market, underscoring the challenge facing the global drugs industry to help control the virus.

"We may have vaccines that look effective after one year, but to then manufacture billions of doses and get them to people, I think everybody expects two years," he said.

"If you look at measles and polio, where there was a desperate urgency, it still took 4-5 years to develop an effective vaccine."

In terms of pricing, Petrovsky said COVID-19 vaccines could potentially cost between $20 to $200 per dose, depending on the technology's manufacturing cost. He said more effective vaccines, or those with fewer or no side effects may sell at a higher price.

Pfizer's deal with the U.S. government to sell 100 million doses for $2 billion "indicates that the price for a very large volume of vaccine will be around $20, but potentially on the private market, it may be $40-$50 by the time you have mark-ups by chemists and you get to retail," Petrovsky said.

Source; Reuters

Tags : #VaxinePtyLtd #CovidVaccine #Pfizer #USGovernment #NikolaiPetrovsky #MediTox #LatestCovidVaccineNews #LatestCovidNews

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026